Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Cantor Fitzgerald
Cerilliant
Citi
Chubb
Cipla
US Department of Justice
QuintilesIMS
Boehringer Ingelheim
Fish and Richardson

Generated: October 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,537,983

« Back to Dashboard

Which drugs does patent 6,537,983 protect, and when does it expire?


Patent 6,537,983 protects BREO ELLIPTA and is included in one NDA.

This patent has one hundred and fifty-two patent family members in forty countries.

Summary for Patent: 6,537,983

Title: Anti-inflammatory androstane derivatives
Abstract:According to one aspect of the invention, there is provided a pharmaceutical formulation for administration by inhalation comprising a compound of formula (I), ##STR1## wherein R.sub.1 represents C.sub.1-6 alkyl or C.sub.1-6 haloalkyl; R.sub.2 represents --C(.dbd.O)-aryl or --C(.dbd.O)-heteroaryl; R.sub.3 represents hydrogen, methyl (which may be in either the .alpha. or .beta. configuration) or methylene; R.sub.4 and R.sub.5 are the same or different and each represents hydrogen or halogen; and ----- represents a single or a double bond; and salts and solvates thereof together with a long-acting .beta..sub.2 -adrenoreceptor agonist which formulation has a therapeutically useful effect in the treatment of inflammatory disorders of the respiratory tract over a period of 24 hours or more.
Inventor(s): Biggadike; Keith (Stevenage, GB), Jones; Paul Spencer (Stevenage, GB), Payne; Jeremy John (Stevenage, GB)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Application Number:10/066,961
Patent Claim Types:
see list of patent claims
Formulation; Compound; Use; Composition; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Glaxo Grp Ltd
BREO ELLIPTA
fluticasone furoate; vilanterol trifenatate
POWDER;INHALATION204275-001May 10, 2013RXYesYes► Subscribe► SubscribeY INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
Glaxo Grp Ltd
BREO ELLIPTA
fluticasone furoate; vilanterol trifenatate
POWDER;INHALATION204275-001May 10, 2013RXYesYes► Subscribe► SubscribeY INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS
Glaxo Grp Ltd
BREO ELLIPTA
fluticasone furoate; vilanterol trifenatate
POWDER;INHALATION204275-002Apr 30, 2015RXYesYes► Subscribe► SubscribeY INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,537,983

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0108800Apr 07, 2001

Non-Orange Book Patents for Patent: 6,537,983

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,787,532 Formulation containing anti-inflammatory androstane derivatives► Subscribe
7,629,335Anti-inflammatory androstane derivative► Subscribe
7,541,350Formulation containing anti-inflammatory androstane derivative► Subscribe
7,498,32117.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents► Subscribe
6,750,210 Formulation containing novel anti-inflammatory androstane derivative► Subscribe
6,878,698 Anti-inflammatory androstane derivatives► Subscribe
7,531,528Formulation containing anti-inflammatory androstane derivatives► Subscribe
7,101,866Anti-inflammatory androstane derivative► Subscribe
6,777,399 Anti-inflammatory androstane derivative compositions► Subscribe
7,592,329Crystalline complexes of fluticasone-2-furoate► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,537,983

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine77656► Subscribe
Taiwan200400837► Subscribe
Taiwan200302831► Subscribe
TaiwanI284646► Subscribe
TaiwanI244486► Subscribe
Slovakia287576► Subscribe
Slovakia1422003► Subscribe
Slovenia2348032► Subscribe
Slovenia1775305► Subscribe
Slovenia1539796► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Merck
Deloitte
Johnson and Johnson
Moodys
Julphar
Chubb
Mallinckrodt
UBS
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot